2022
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma
Hasanov E, Yeboa D, Tucker M, Swanson T, Beckham T, Rini B, Ene C, Hasanov M, Derks S, Smits M, Dudani S, Heng D, Brastianos P, Bex A, Hanalioglu S, Weinberg J, Hirsch L, Carlo M, Aizer A, Brown P, Bilen M, Chang E, Jaboin J, Brugarolas J, Choueiri T, Atkins M, McGregor B, Halasz L, Patel T, Soltys S, McDermott D, Elder J, Baskaya M, Yu J, Timmerman R, Kim M, Mut M, Markert J, Beal K, Tannir N, Samandouras G, Lang F, Giles R, Jonasch E. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA A Cancer Journal For Clinicians 2022, 72: 454-489. PMID: 35708940, DOI: 10.3322/caac.21729.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaManagement of brain metastasesBrain metastasesCell carcinomaManifestation of renal cell carcinomaResistance to systemic treatmentMultimodal treatment strategiesGuiding treatment decisionsSystemic treatmentCurrent management strategiesPoor prognosisMetastasis tumorsImmune biologyBrain metastasis tumorsRadiation treatmentTreatment strategiesInternational group of expertsCarcinomaMetastasisTreatment decisionsConsensus statementPatientsInterdisciplinary consensusUnmet patient needsLiterature review
2020
Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients
Miccio JA, Talcott WJ, Jairam V, Park HS, Yu JB, Leapman MS, Johnson SB, King MT, Nguyen PL, Kann BH. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer And Prostatic Diseases 2020, 24: 414-422. PMID: 32989262, DOI: 10.1038/s41391-020-00291-3.Peer-Reviewed Original ResearchConceptsProstate cancer-specific survivalLow-risk prostate cancerExternal beam radiotherapyTreatment selection biasOverall survivalRadical prostatectomyProstate cancerOS differenceLow-risk prostate cancer patientsCancer-specific survivalEnd Results (SEER) databaseProstate cancer patientsClinical trial designEffectiveness researchComparative effectiveness researchPropensity-score matchingMethodsThe SurveillanceTreatment guidelinesResults databaseEntire cohortResultsA totalCancer patientsTreatment modalitiesNational registryPatient managementProceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop
Yu JB, Brock KK, Campbell AM, Chen A, Diaz R, Escorcia F, Gupta G, Hrinivich WT, Joseph S, Korpics M, Onderdonk BE, Pandit-Taskar N, Wood B, Woodward WA. Proceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: 539-545. PMID: 32434040, DOI: 10.1016/j.ijrobp.2020.05.018.Peer-Reviewed Original Research
2018
Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
Johnson S, Yu J. Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. Current Oncology Reports 2018, 20: 66. PMID: 29959582, DOI: 10.1007/s11912-018-0711-0.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyHumansMuscle NeoplasmsNeoplasm InvasivenessOrgan Sparing TreatmentsPrognosisUrinary Bladder NeoplasmsConceptsBladder-preserving trimodality therapyTrimodality therapyRadical cystectomyBladder cancerMuscle-invasive urothelial carcinomaMuscle-invasive bladder cancerAlternative to cystectomySatisfactory quality of lifeBladder preservationOncological outcomesUrothelial carcinomaCystectomyFuture trialsBladderFunctional outcomesTherapyDisease outcomePatientsQuality of lifeTrimodalityCancerOutcomesCarcinoma
2016
Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer
Dosoretz A, Yu J. Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer. Journal Of Clinical Oncology 2016, 34: 1718-1722. PMID: 27001587, DOI: 10.1200/jco.2015.66.3237.Peer-Reviewed Original ResearchMeSH KeywordsAgedAndrogen AntagonistsCombined Modality TherapyHumansMaleNeoplasm GradingProstate-Specific AntigenProstatic NeoplasmsRadiotherapy DosageConceptsExternal-beam radiotherapyDigital rectal examinationPalpable diseaseRectal examinationGleason 3+3 diseaseOncology Grand Rounds seriesHigh-grade prostate cancerMagnetic resonance imaging-ultrasound fusionMultiparametric magnetic resonance imagingAdjacent normal prostatePositive biopsy coresUltrasound-guided biopsyInguinal hernia repairT2-weighted imagesJournal of Clinical OncologyPatient's medical historyMagnetic resonance imagingHypointense featuresGleason 4Prostate volumePSA levelsAndrogen deprivationCataract surgeryIntraprostatic lesionsBiopsy cores
2012
Status Quo—Standard-of-Care Medical and Radiation Therapy for Glioblastoma
Becker K, Yu J. Status Quo—Standard-of-Care Medical and Radiation Therapy for Glioblastoma. The Cancer Journal 2012, 18: 12-19. PMID: 22290252, DOI: 10.1097/ppo.0b013e318244d7eb.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, AlkylatingBrain NeoplasmsCombined Modality TherapyDacarbazineGlioblastomaHumansMagnetic Resonance ImagingTemozolomideConceptsRadiation therapyStandard treatmentMonths of diagnosisCases of glioblastomaDevelopment of temozolomideAdjuvant radiationAdjuvant temozolomideAggressive tumorsImproved survivalTreatment courseChemotherapy agentsSurgical interventionChemotherapeutic agentsCancer morbidityTemozolomideGlioblastomaMonthsSurvivalTherapyTreatmentChemoradiationCytoreductionStuppChemotherapyBiopsy